Ian Flinn, MD, PhD | Authors


The Safety and Efficacy of Venetoclax/Obinutuzumab Combo in CLL

December 13, 2017

Ian Flinn, MD, Director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the safety, efficacy, and MRD negativity of a combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.